# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

> **NCT01124851** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 36 (actual)

## Conditions studied

- Sleep Disorder

## Interventions

- **DRUG:** ABT-652
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01124851
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2011-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124851, "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01124851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*